Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pharma companies may...

    Pharma companies may report subdued performance in Q2 FY17: Report

    Written by savita thakur thakur Published On 2016-10-17T10:44:52+05:30  |  Updated On 17 Oct 2016 10:44 AM IST
    Pharma companies may report subdued performance in Q2 FY17: Report

    Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said.


    "We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in Q2 FY17 led by the quiet US business on lack of fresh ANDA approvals due to the pending US FDA issues.


    "Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17," Reliance Securities said in its report here.


    "However, industry expects strong recovery in domestic formulations business for most companies under our coverage driven by strong monsoon, while favourable y-o-y movement in non-USD currencies and new drugs approvals will drive growth in emerging markets," the report said.


    It said EBITDA margins will continue to be under pressure on account of increased R&D spending and adverse product-mix.


    "We continue to remain positive on long-term prospects of the pharma sector and recommend being stock-specific," it added.


    The US remains mainstay for most companies, contributing 55-60 per cent of total exports.


    Measures like aggressive R&D spend and scale-up in complex ANDA filings are considered to be the key re-rating triggers, it said.


    However, few operational metrics have exhibited lack of momentum like critical facilities under US FDA lens, channel consolidation and slowdown in approvals.


    While Sun Pharma Halol warning letter and Cadila's Moraiya warning letter are awaiting re-inspection from the US FDA, Dr Reddy's pending Form 483 to three plants is still undergoing Corrective and Preventive Action (CAPA) process and it is expected to submit re-inspection request shortly.


    Lupin is awaiting the US FDA resolution for its Goa plant.


    "The US revenue for the companies under our coverage universe is expected to decline sequentially by 5-6 per cent owing to increased competition leading to price erosion in base product portfolio, Gleevec/Glumetza 180 days exclusivity ends and lack of meaningful launches," it added.


    Pharma companies are likely to witness strong recovery in domestic formulations business.


    "We expect strong recovery in India formulations business for most companies driven by strong monsoon," it said.


    The Indian pharma market has reported strong growth of 15 per cent and 18 per cent in July and Aug, respectively.


    It is expected to witness 16-17 per cent CAGR in next few years, led by new product launches.

    Abbreviated New Drug ApplicationANDACAPACorrective and Preventive ActionDr Reddy'sEBITDAPharma companiesRelianceUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok